Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > PP amount?

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Jul 02, 2024 2:58pm

163 Views

Post# 36114922

RE:PP amount?

A particular number doesn't matter. What matters is whatever "x" amount is required to get us to a BTD & a significant step closer to either an AA or traditional approval.

ImmunityBio orchestrated a $310 million royalty financing & equity deal in December 2023 with Oberland Captial, which was for a single indication drug at the pre-BLA approval stage. You could make a strong case that a BTD (pre-NDA approval) for a potentially much more versatile drug is worthy of a sizeable fraction of that...

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles